Mayne Pharma : 2021 Full Year Investor Presentation

Mayne Pharma Group Limited

FY21 Results Presentation 27 August 2021

Scott Richards, CEO

Peter Paltoglou, CFO

Disclaimer

The information provided is general in nature and is in summary form only. It is not complete and should be read in conjunction with the company's audited Financial Statements and market disclosures. This material is not intended to be relied upon as advice to investors or potential investors.

Non-IFRS information

• Other than as indicated, the financial information contained in this document is directly extracted or calculated from the audited Financial Statements. Throughout this document some non-IFRS financial information is stated, excluding certain specified income and expenses. Results excluding such items are considered by the Directors to provide a meaningful basis for comparison from period to period.
• Earnings before interest, tax, depreciation and amortisation (EBITDA) - a non-IFRS term - is considered by Directors to be a meaningful measure of the operating earnings and performance of the Group and this information may be useful for investors.
• The non-IFRS financial information has not been audited by the Group's auditors.

Forward looking statements

• This presentation contains forward-looking statements that involve subjective judgement and analysis and are subject to significant uncertainties, risks and contingencies, many of which are outside the control of, and are unknown to the Company. These forward looking statements use words such as 'potential', 'expect', 'anticipate', 'intend', 'plan' and 'may', and other words of similar meaning. No representation, warranty or assurance (express or implied) is given or made in relation to any forward looking statement by any person (including the Company). Actual future events may vary materially from the forward looking statements and the assumptions on which the forward looking statements are based. Given these uncertainties, readers are cautioned not to place undue reliance on such forward looking statements. Subject to the Company's continuous disclosure obligations at law and under the listing rules of the Australian Securities Exchange, the Company disclaims any obligation to update or revise any forward looking statements. The factors that may affect the Company's future performance include, among others: changes in economic conditions, changes in the legal and regulatory regimes in which the Company operates, litigation or government investigations, decisions by regulatory authorities, changes in behaviour of major customers, suppliers and competitors, interruptions to manufacturing or distribution, the success of research and development activities and research collaborations and the Company's ability to protect its intellectual property.

Other

• A glossary of industry terminology is contained in the Mayne Pharma Annual Report which can be accessed atmaynepharma.com/investor-relations/results-reports and product descriptions are detailed atmaynepharma.com/us-products andmaynepharma.com/australian- products.
• ACTIKERALL®, NEXTSTELLIS®, NUVARING®, SOLARAZE®, SOLTAMOX® and UROREC® are trademarks of third parties.

2

Business and strategy update

Operating momentum through a challenging year1

A$401m	A$66m	A$75m	A$26m
reported sales	reported EBITDA	underlying EBITDA2	opex2 reduction
(-3% YOY in	(-5% YOY in	(-10% YOY in	(-13% YOY in constant
constant currency)	constant currency)	constant currency)	currency)

1	80	11	70
'first pass' NDA	personnel added	dermatology and	active third party
approval for	to new US	women's health	contract development
NEXTSTELLIS®	women's health	products added	projects globally
	team	to portfolio	(+17% YOY)
		targeting
		US$650m in
		IQVIA sales3
1. FX had adverse impact on earnings with the average AUD:USD rate of 0.747 in FY21 v 0.671 in FY20		4
2. Excludes NEXTSTELLIS® set up costs

3. IQVIA, MAT Sales, June 2021

Achieved strategic rebalance of the business to more sustainable categories

								Gross profit by type1
			FY19										FY21
										18%
					27%			29%
	44%							9%
					10%		16%
										26%
	5%	14%						2%
								56%
													82%
Dermatology			Women's health				Infectious disease		US Contract Services		International			US retail generic

1. Reported gross profit adjusted for the internal manufacturing margin on US products included in US Contract Services and International in both periods

5